Amgen Inc.
Amgen revenue misses analyst estimates

Amgen Inc., the world's largest biotechnology company by sales, reported first-quarter revenue below analysts' estimates on lower-than-expected demand of its top drug, Enbrel. Quarterly sales increased 6.6 percent to $4.52 billion compared with a year earlier, missing the $4.75 billion average of 19 analysts' estimates compiled by Bloomberg. Amgen is seeking to expand its portfolio of products from Enbrel, its arthritis drug, and its anemia medicines led by Neulasta. The Thousand Oaks, California-based company acquired Kyprolis for blood cancer in its purchase last year of Onyx Pharmaceuticals Inc. and an experimental cholesterol drug produced successful results in a...